Business
Syntopix to research biofilms
Syntopix to research biofilms.
About this update from Gunsynd Plc
[{"type":"text","content":"\n RNS Number : 5375Z Syntopix Group plc 17 January 2011 \n \n\n \n \n\n\n\n\nPress Release \n\n\n17 January 2011\n\n\n\n\n \nSyntopix Group plc\n(\"Syntopix\" or \"the Company\")\n \nSyntopix to research biofilms for Beiersdorf AG\n \n \nSyntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, is pleased to announce that it has signed a research agreement with Beiersdorf AG (\"Beiersdorf\"), an international branded consumer goods company with a focus on skin care. Beiersdorf, which owns skin care brands such as NIVEA and La Prairie, will pay Syntopix a research contract fee to establish and validate screening assays to improve topical antimicrobial efficacy.\n \nAntimicrobial efficacy on skin surfaces is influenced by specific restrictions that affect delivery and bioavailability of actives, for example release from the formulation or skin penetration. Under the terms of the agreement Syntopix will develop new lab-based assays to help examine the effective delivery of active ingredients in order to maximize their bioavailability on skin. \n \nDr Stephen Jones, CEO of Syntopix, says: \"I am delighted to be working with Beiersdorf. Syntopix's wider work on skin disorders and oral health has given our team a deep understanding of factors affecting the topical efficacy of antimicrobials. Our assays will facilitate the development of new antimicrobial strategies to address this important challenge.\" \n \nDr. Heiner Max, Head of Research Personal Care of Beiersdorf adds: \"As one of the world's leading cosmetics companies, which is involved in the development and manufacture of skin care products, Beiersdorf's expertise is closely aligned with that of Syntopix. Together we are in a strong position to work towards developing unique and effective products.\"\n \n- Ends -\n \nFor further information, please contact:\n \n\n\n\n\nSyntopix Group plc\n\n\n\n\n\n\n\nDr Stephen Jones, Chief Executive Officer\n\n\n+44 (0)845 125 9204\n\n\n\n\nTom Bannatyne, Chairman\n\n\nwww.syntopix.com\n\n\n\n\n \n\n\n\n\nZeus Capital Ltd\n\n\n\n\n\n\n\nAlex Clarkson\n\n\nTel: +44(0)161 831 1512 \n\n\n\n\nTom Rowley\n\n\nwww.zeuscapital.co.uk\n\n\n\n\n \n\n\n\n\nXCAP Securities Plc\n\n\n\n\n...